The study aims to include women carrying a germline P/LP variant (BRCA1, BRCA2, or PALB2), or >5% Tyrer–Cuzick breast cancer risk at ten years, or with a previous diagnosis with intraepithelial neoplasia within the last three years [119]. The gene discussed is BRCA2; the disease is breast carcinoma.